You are here

Article Text

Article menu

Download PDFPDF

Original article
Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series
  1. A L Gomes1,
  2. A Gouveia2,3,5,
  3. A F Capelinha2,4,5,
  4. D de la Cruz4,
  5. P Silva2,4,5,
  6. R M Reis1,
  7. A Pimenta3,4,5,
  8. J M Lopes2,4,5
  1. 1
    Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
  2. 2
    IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
  3. 3
    Department of Surgery, Porto University, Porto, Portugal
  4. 4
    Department of Pathology, H.S. João, Porto University, Porto, Portugal
  5. 5
    Medical Faculty of Porto University, Porto, Portugal
  1. ProfessorDr José Manuel Lopes, Rua Roberto Frias, s/n, 4200-465 Porto, Portugal; jmlopes{at}ipatimup.pt

Abstract

Aim: To assess KIT and PDGFRA mutations frequencies in a Portuguese series of gastrointestinal stromal tumours (GISTs).

Methods: 78 GISTs were evaluated for CD117 expression and screened for mutations in KIT (exons 9, 11, 13, 14 and 17) and PDGFRA (exons 12, 14 and 18) genes.

Results: KIT activating mutations were identified in 44 (56%) of the 78 GISTs. Forty cases (91%) presented a mutation in KIT exon 11, and 4 (9%) in exon 9. One case showed a 4 bp deletion in intron 14. PDGFRA mutations were observed in 5 cases (6%): 2 (3%) in exon 12 and 3 (4%) in exon 18. Survival analysis was performed in 63 of the 78 GISTs. The presence of mutated KIT was significantly correlated with shorter survival of patients (p = 0.0460), and inversely associated with epithelioid histological type of GISTs (p = 0.0064).

Conclusions: Overall, the incidence of both KIT and PDGFRA mutations in these Portuguese series was 63%, being in agreement with other studies, mainly of Iberian populations. The great majority of mutations were located in KIT exon 11, statistically associated with worse prognosis and indicative of favourable response to imatinib-based therapy in this Portuguese series of GISTs.

https://doi.org/10.1136/jcp.2007.047043

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: Supported by NOVARTIS Oncology, Portugal. ALG is the recipient of fellowship grant (SFRH/BI/15257/2004) from FCT, Lisbon, Portugal.

    • Competing interests: None declared.